Health Care Biotech and Pharmaceuticals


  • US government targets new drug

    CNBC's Meg Tirrell reports on a new tactic by some in Congress to question the price of high-cost drugs.

  • Elisabeth Holmes, founder and CEO of Theranos.

    A study found that Theranos produces more irregular results than conventional laboratories, The New York Times reports.

  • Headache drug wars

    CNBC's Meg Tirrell reports on Alder Biopharmaceuticals' chronic migraine drug trial and how other pharma companies are developing new treatments and therapies, as well as the latest on Valeant CEO Mike Pearson's subpoena.

  • Valeant CEO subpoenaed to Senate panel

    CNBC's Meg Tirrell reports that Valeant CEO Mike Pearson has received a subpoena to testify to a Senate panel.

  • The headquarters of Gilead Sciences in Foster City, Calif.

    A federal jury has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.

  • Bill Ackman at the New York Stock Exchange.

    U.S. legislators have asked William Ackman's hedge fund for information on Valeant, according to a person familiar with the matter.

  • Pills

    Let the free market decide the availability, cost and need for any drug or treatment, says Jake Novak.

  • John Milligan, Gilead Sciences

    Merck's claims upheld in a California court, but Gilead told CNBC that it will appeal the case.

  • Aedes aegypti mosquitos are seen in a lab at the Fiocruz institute on January 26, 2016 in Recife, Pernambuco state, Brazil.

    South Korea reported its first confirmed case of the Zika virus on Tuesday, its center for disease control said.

  • Michael Pearson, CEO of Valeant Pharmaceuticals.

    Valeant announces that CEO Mike Pearson is leaving and that former CFO Howard Schiller refused to quit the board to make room for Bill Ackman.

  • A file photo of an Ebola vaccine trial in Liberia last February.

    Chinese authorities are hunting 300 people suspected of illegally selling spoiled vaccines to medical centers across the country, state media said.

  • An aedes aegypti mosquitoe is seen inside a test tube as part of a research on preventing the spread of the Zika virus and other mosquito-borne diseases at a control and prevention center in Guadalupe, neighbouring Monterrey, Mexico, March 8, 2016.

    Intrexon CEO tells CNBC's Power Lunch that he would not go to Brazil with Zika virus outbreak.

  • Valeant's dismal week

    CNBC's Meg Tirrell gives a recap on Valeant Pharma's troubles this week including their plunging share price and looming debt timeline.

  • Martin Shkreli former CEO of Turing Pharmaceuticals LLC.,

    Howard Dorfman testified he was fired weeks after telling CEO Martin Shkreli the increase "was not justified." USA Today reports.

  • Trading biotech, health care unknowns

    Biotechs are still sinking, so when should you buy these stocks? The FMHR traders and Stephanie Link, TIAA Equities portfolio manager, share their strategy.

  • Bearish case for Valeant

    Les Funtleyder, Asset Management Portfolio Manager at ESquared, gives his take on Valeant Pharmaceuticals and the pharma and health care sectors.

  • Valeant's next move

    CNBC's Meg Tirrell looks at the next steps for beleaguered Valeant Pharma, including their looming debt deadlines and possible divestitures.

  • Bill Ackman

    After Valeant took a bite out of Bill Ackman's hedge fund, the billionaire described his firm's standing to CNBC's Scott Wapner.

  • Sir Andrew Witty, CEO, GlaxoSmithKline.

    GlaxoSmithKline said its CEO Andrew Witty would retire in 12 months, prompting Britain's biggest drugmaker to start a formal search for his successor.

  • The headquarters of Valeant Pharmaceuticals International in Laval, Quebec.

    Creditors of Valeant Pharmaceuticals are beginning to demand new terms that could further pressure the drugmaker's business model, sources said.

Contact Biotech and Pharma


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about about our products and service. Privacy Policy.


  • Dan Mangan is a reporter covering health care for

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.